Neurol. praxi. 2024;25(2):116-122 | DOI: 10.36290/neu.2023.070

The benefit of cognitive assessment in neurodegenerative diseases

Mgr. Nela Němcová Elfmarková, Ph.D.^{1, 3}, Mgr. Kristína Mitterová, Ph.D.^{1, 3}, Mgr. Luboš Brabenec, Ph.D.^{1, 3}, Mgr. Jan Farkaš^{1, 3}, doc. Mgr. et Mgr. Tomáš Nikolai, Ph.D.^{4, 5}, prof. MUDr. Irena Rektorová, Ph.D.^{1, 2, 3}

¹ Středoevropský technologický institut - CEITEC, Masarykova univerzita, Aplikované neurovědy, Brno

² Fakultní nemocnice u sv. Anny, I. neurologická klinika, Brno

³ Mezinárodní centrum klinického výzkumu - ICRC, Fakultní nemocnice u sv. Anny, Brno

⁴ Univerzita Karlova, Filozofická fakulta, Katedra psychologie, Praha

⁵ Fakultní nemocnice Motol, Oddělení klinické psychologie, Praha

The article focuses on the diagnosis of cognitive decline in neurodegenerative diseases, with an emphasis on mild cognitive impairment (MCI). The diagnosis of MCI is crucial for early intervention and symptomatic treatment, and therefore the selection of appropriate screening and neuropsychological tests is important. We focus on tests that are recommended for patients with Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and dementia with Lewy bodies. A sensitive neuropsychological assessment is also crucial for the prediction of progression to dementia. It is however necessary to take into account the demographic characte­ristics of the patients and their premorbid intellect.

Keywords: mild cognitive impairment, dementia, Alzheimer's disease, Parkinson's disease, Lewy­‑body disease, frontotemporal dementia, diagnostic criteria, cognitive assessment, screening tests.

Received: August 3, 2023; Revised: November 10, 2023; Accepted: November 17, 2023; Prepublished online: November 17, 2023; Published: April 16, 2024  Show citation